Inhibition of ischemia and reflow-induced liver injury by an SOD derivative that circulates bound to albumin.
Ischemia followed by reflow often results in tissue injury. Although reactive oxygens seem to play an important role in the pathogenesis of postischemic reflow-induced tissue injury, the mechanism and an efficient way to inhibit oxidative injury are not known. We studied the mechanism by which hepatic transport function was inhibited by a transient occlusion followed by reflow of the portal vein and hepatic artery by using a superoxide dismutase (SOD) derivative (SM-SOD) which circulates bound to albumin with a half-life of 6 h. Occlusion of the hepatic vessels for 20 min followed by reflow for 60 min significantly inhibited transhepatic transport of cholephilic ligands, such as bromosulfophthalein (BSP) and taurocholic acid. Intravenous administration of SM-SOD markedly inhibited the reflow-induced decrease in transhepatic transport of these ligands. Thiobarbituric acid - reactive metabolites (TBAR) in the liver and plasma remained unchanged during occlusion and reflow, while TBAR in the bile increased significantly. Intravenous injection of SM-SOD inhibited the reflow-induced increase in biliary TBAR. Xanthine oxidase activity in plasma also increased during occlusion and reflow by an SM-SOD-inhibitable mechanism. Polymorphonuclear leukocyte-dependent chemiluminescence of the peripheral blood remained unchanged during occlusion, but increased markedly with time after reflow. SM-SOD also inhibited the increase in chemiluminescence almost completely. These and other results suggested that the superoxide radical and/or its metabolite(s) might play an important role in the pathogenesis of the reflow-induced liver injury and that SM-SOD might be useful for studying the mechanism for tissue injury caused by oxygen toxicity.
Kawamoto
S
S
Department of Biochemistry, Kumamoto University Medical School, Japan.
Inoue
M
M
Tashiro
S
S
Morino
Y
Y
Miyauchi
Y
Y
D000818:Animals; D001646:Bile / Q000187:drug effects / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D006207:Half-Life; D007511:Ischemia / Q000503:physiopathology* / Q000517:prevention & control; D007700:Kinetics; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008102:Liver Circulation / Q000187:drug effects*; D008297:Male; D008298:Maleates / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D011108:Polymers / Q000494:pharmacology / Q000627:therapeutic use; D011137:Polystyrenes / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D011919:Rats, Inbred Strains; D015424:Reperfusion; D013438:Sulfhydryl Compounds / Q000378:metabolism; D013482:Superoxide Dismutase / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D013997:Time Factors; D014969:Xanthine Oxidase / Q000097:blood
D008298:Maleates; D011108:Polymers; D011137:Polystyrenes; D013438:Sulfhydryl Compounds; D013482:Superoxide Dismutase; D014969:Xanthine Oxidase